,

Sanofi Has the Enzyme. It Just Can't Ship It.


An ongoing shortage of Sanofi’s Pompe disease treatment is forcing some patients to miss critical doses. They worry their health is at risk.

  •   2 min reads
Sanofi Has the Enzyme. It Just Can't Ship It.

Sanofi has a Pompe disease shortage that is not a shortage.

Read that again. Then ask Sanofi to read it, because the company has been saying it for months.

,Sanofi says the constraint is not a shortage of the drug itself, but a bottleneck in final manufacturing, quality-control and batch-release at Waterford., The enzyme exists. It is sitting somewhere in Ireland, waiting for paperwork. A lifesaving drug, held up like a package at customs.

The patients are not waiting for a package. ,The shortage has lasted more than three months, forcing some patients to miss critical infusions., ,Patients typically get these drugs every two weeks., Do the math. That is a lot of missed appointments.

Monique Griffin of Orlando has taken Lumizyme since 2010. ,She uses a wheelchair due to Pompe disease and had an infusion canceled because of the shortage.,

Chelsey McGee's son Logan is 10. ,He has taken Lumizyme every two weeks since infancy. His infusions haven't been canceled yet, but she fears missing even one will damage his heart.,

Sanofi's response is a model of corporate calm. ,A spokesperson said there were no quality issues and that the company is committed to making sure the most vulnerable patients are treated first., Triage, in other words. Sanofi has decided who goes first. Nobody voted.

The company also advises patients to talk to a doctor before switching drugs, ,noting the medicines are not interchangeable., So the backup plan has a warning label.

Here is the fine print. ,The shortage followed an FDA warning about manufacturing problems at Sanofi's Waterford plant., But ,the warning letter named two other products, Thymoglobulin and Altuviiio, not the Pompe enzymes., One plant. Several products. One very long queue.

And the timeline? ,Sanofi expects the shortage to ease in the coming months but has not offered a firm timeline for full recovery., Coming months. Not a date. A vibe.

I look at charts. Charts do not care about Waterford. Somewhere a retail trader is drawing a support line under Sanofi's stock and calling it a thesis. Meanwhile a ten-year-old's heart is on a two-week schedule that a batch-release queue is rewriting.

The enzyme is not missing. The patients just have no way to get it.

Photo by on Unsplash

Related Posts

↑

The Noise is free. If Phil's commentary made you laugh or think, he accepts tips. No pressure — the sarcasm was complimentary.

Leave a Tip